A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer
Hirt et al.1 report an automated, high-throughput drug screening platform for organoid cultures to enable repurposing of previously approved drugs for pancreatic cancers harboring specific genetic alterations. The pancreatic cancer organoid biobank also represents a valuable tool to uncover new drug...
Main Authors: | Sara Mainardi, Rene Bernards |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-02-01
|
Series: | Cell Genomics |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666979X22000179 |
Similar Items
-
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer
by: Sander Mertens, et al.
Published: (2023-04-01) -
Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
by: Matthew Cannon, et al.
Published: (2020-07-01) -
Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
by: Evangelia Sereti, et al.
Published: (2023-03-01) -
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
by: Carla S Verissimo, et al.
Published: (2016-11-01) -
Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
by: Xingfeng He, et al.
Published: (2023-05-01)